Intra-Cellular Therapies
(NASDAQ:ITCI)
$65.56
-1.44[-2.15%]
At close: May 9
$65.56
0[0.00%]
After Hours: 4:00PM EDT
Q1 2024 Earnings were released on Tue May 7th, before the market open
The most recent conference call was at 8:30 AM, 2 days ago Click to view past webcast
OverviewNewsEarningsGuidanceDividendsAnalyst RatingsInsider TradesShort Interest

Intra-Cellular Therapies Stock (NASDAQ:ITCI), Quotes and News Summary

Intra-Cellular Therapies Stock (NASDAQ: ITCI) stock price, news, charts, stock research, profile.

Open$66.970
Close$65.560
Volume / Avg.767.145K / 977.916K
Day Range65.450 - 67.230
52 Wk Range45.500 - 84.890
Market Cap$6.921B
P/E Ratio-
Dividend Yield-
ExchangeNASDAQ
RSI
40
Short Interest
3.9%
Days to Cover6.95

Recent News

Abbott Laboratories, U.S. Bancorp And 3 Stocks To Watch Heading Into Wednesday
With U.S. stock futures trading higher this morning on Wednesday, some of the stocks that may grab investor focus today are as follows:
Avi Kapoor
Why Skillsoft Shares Are Trading Lower By Around 27%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Skillsoft Corp. (NASDAQ: SKIL) fell sharply during Tuesday’s session after the company reported mixed fourth-quarter financial results and issued FY25 revenue guidance below estimates.
Avi Kapoor
Intra-Cellular Stock Rallies On Successful Late-Stage Depression Treatment Study
Unlock new hope for major depressive disorder with Lumateperone 42 mg. Results from Intra-Cellular's Study 501, show significant symptom relief as adjunctive therapy to antidepressants.
Vandana Singh
-%

Financials

Quarterly
Annual
Name
Revenue
Change
Gross
Change
EBITDA
Change
EBIT
Change
Earnings
Change
Analyst Trend
2
Dec 23
3
1
Jan
5
Feb
10
1
Apr
2
May
Buy
Hold
Sell
Strong Sell
Analyst Rating
12345
4.1
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Compare

EPS worse than industry
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.
ITCI
NVO

FAQ

Q

How do I buy Intra-Cellular Therapies (ITCI) stock?

A

You can purchase shares of Intra-Cellular Therapies (NASDAQ: ITCI) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are Intra-Cellular Therapies's (ITCI) competitors?

A

Other companies in Intra-Cellular Therapies’s space includes: Novo Nordisk (NYSE:NVO), Johnson & Johnson (NYSE:JNJ), Merck & Co (NYSE:MRK), Novartis (NYSE:NVS) and Pfizer (NYSE:PFE).

Q

What is the target price for Intra-Cellular Therapies (ITCI) stock?

A

The latest price target for Intra-Cellular Therapies (NASDAQ: ITCI) was reported by Needham on Wednesday, May 8, 2024. The analyst firm set a price target for 90.00 expecting ITCI to rise to within 12 months (a possible 37.28% upside). 37 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Intra-Cellular Therapies (ITCI)?

A

The stock price for Intra-Cellular Therapies (NASDAQ: ITCI) is $65.56 last updated May 9, 2024 at 4:00 PM EDT.

Q

Does Intra-Cellular Therapies (ITCI) pay a dividend?

A

There are no upcoming dividends for Intra-Cellular Therapies.

Q

When is Intra-Cellular Therapies (NASDAQ:ITCI) reporting earnings?

A

Intra-Cellular Therapies’s Q2 earnings are confirmed for Thursday, August 1, 2024.

Q

Is Intra-Cellular Therapies (ITCI) going to split?

A

There is no upcoming split for Intra-Cellular Therapies.

Q

What sector and industry does Intra-Cellular Therapies (ITCI) operate in?

A

Intra-Cellular Therapies is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.

People Also Watch